Edita Gasiuniene1, Ieva Janulaityte2, Zivile Zemeckiene3, Diana Barkauskiene4, Brigita Sitkauskiene1. 1. Department of Immunology and Allergology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 2. Department of Pulmonology, Laboratory of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania. 3. Department of Laboratory Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania. 4. Department of Pulmonology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Abstract
IL-33 is a recently discovered cytokine which plays an important role in asthma pathogenesis. AIM: To evaluate serum IL-33 in patients with asthma and healthy controls, and to evaluate the association of IL-33 with different asthma phenotypes. METHODS: Patients with asthma (n = 115) and healthy subjects (n = 85) were included in the study. Subjects with asthma were divided into groups according to their phenotype: allergic/non-allergic, eosinophilic/non-eosinophilic, obese/non-obese and severity according to GINA (mild, moderate and severe). The concentration of IL-33 in serum was measured by standardized enzyme-linked immunosorbent assay. RESULTS: The level of IL-33 was significantly higher in patients with asthma when compared to healthy subjects (672.73 ± 104.47 pg/mL vs 268.52 ± 27.56 pg/mL, P < 0.05). IL-33 was also higher in the allergic asthma group patients when compared to non-allergic asthmatics (844.61 ± 152.08 pg/mL vs 369.56 ± 77.94 pg/mL, P < 0.05). There was a significantly higher serum IL-33 level in the eosinophilic asthma group when compared to the group of non-eosinophilic asthma patients (1001.10 ± 199.11 pg/mL vs 337.49 ± 72.68 pg/mL, P < 0.01). We did not find a significant difference in serum IL-33 level between different asthma severity groups, obese and non-obese asthmatics. CONCLUSION: IL-33 is increased in asthma patients, particularly in some phenotypes: allergic asthma and eosinophilic asthma.
IL-33 is a recently discovered cytokine which plays an important role in asthma pathogenesis. AIM: To evaluate serum IL-33 in patients with asthma and healthy controls, and to evaluate the association of IL-33 with different asthma phenotypes. METHODS:Patients with asthma (n = 115) and healthy subjects (n = 85) were included in the study. Subjects with asthma were divided into groups according to their phenotype: allergic/non-allergic, eosinophilic/non-eosinophilic, obese/non-obese and severity according to GINA (mild, moderate and severe). The concentration of IL-33 in serum was measured by standardized enzyme-linked immunosorbent assay. RESULTS: The level of IL-33 was significantly higher in patients with asthma when compared to healthy subjects (672.73 ± 104.47 pg/mL vs 268.52 ± 27.56 pg/mL, P < 0.05). IL-33 was also higher in the allergic asthma group patients when compared to non-allergic asthmatics (844.61 ± 152.08 pg/mL vs 369.56 ± 77.94 pg/mL, P < 0.05). There was a significantly higher serum IL-33 level in the eosinophilic asthma group when compared to the group of non-eosinophilic asthmapatients (1001.10 ± 199.11 pg/mL vs 337.49 ± 72.68 pg/mL, P < 0.01). We did not find a significant difference in serum IL-33 level between different asthma severity groups, obese and non-obese asthmatics. CONCLUSION:IL-33 is increased in asthmapatients, particularly in some phenotypes: allergic asthma and eosinophilic asthma.
Authors: Celeste M Porsbjerg; Asger Sverrild; Clare M Lloyd; Andrew N Menzies-Gow; Elisabeth H Bel Journal: Eur Respir J Date: 2020-11-12 Impact factor: 16.671